CTLA4 and colitis: Another study established thresholds for the SUV95 of different non-target organs for a PET-based diagnosis of therapy-associated colitis, pneumonitis, and thyroiditis, evaluating a cohort of 58 patients during anti-PD-1 or anti-CTLA-4 ICI therapy including 18 patients with irAEs (26) - they observed significantly elevated SUV95 values in organs affected by therapy-associated inflammation.